Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc. (NASDAQ: NVAX) shares were moving to the downside Monday following an update from the company on its coronavirus vaccine program. What Happened: Gaithersburg, Maryland-based Novavax said it has commenced the PREVENT-19 Phase 3 study of its coronavirus vaccine candidate NVX-CoV2373 in the U.S. and Mexico.

Novavax Investors Pull Back As Biopharma Launches Phase 3 Coronavirus Vaccine Study

Novavax Inc. said Monday it is starting a late-stage trial of its COVID-19 vaccine candidate with plans to enroll up to 30,000 volunteers at about 115 sites in the U.S. and Mexico. The trial is being supported by partners of Operation Warp Speed, the federal government program that aims to quickly develop vaccines and therapies, including the Department of Defense and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response.

Novavax starts Phase 3 COVID vaccine trial with plans to enroll 30,000 volunteers in U.S. and Mexico

GAITHERSBURG, Md., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company's COVID-19 vaccine candidate. The trial builds on research from Phase 1/2 studies demonstrating that the vaccine provoked a robust immune response, generated highly neutralizing antibodies against the virus and was generally well-tolerated.

Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico

Johnson & Johnson

Pfizer

3 COVID Vaccine Stocks Smart Investors Are Buying for 2021

Cardiff Oncology

Genprex

Trillium Therapeutics

Vaxart

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19.

5 Biotech Stocks That Generated 1,000%+ Returns In 2020

BioNTech SE

Inovio Pharmaceuticals

Moderna

Telesis Bio Inc

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19

Vaccine specialist Novavax has seen its stock price soar by roughly 25x year to date. While part of the gains were driven by encouraging results for phase 3 trials of the company's NanoFlu flu vaccine back in March, a bulk of the price appreciation is due to the company's development of a Covid-19.

Novavax Stock: What Are The Risks?

A10 Networks

National Vision Hlds

FuelCell Energy

Smith & Wesson Brands

Unisys

VirnetX

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for January 2021.

Top Small Cap Stocks for January 2021

If you're concerned over a regulatory bump in the road, relax, as Novavax stock should still have catalysts to drive the share price higher. The post Don't Let the Vaccine Trial Delay Stop You from Believing in Novavax appeared first on InvestorPlace.

Don't Let the Vaccine Trial Delay Stop You from Believing in Novavax

They are at a critical point. What happens next could push them higher, or result in a big loss.

Is There Still Room for Growth for These 2 Coronavirus Stocks?

Novavax's COVID-19 vaccine has shown efficacy in clinical trials. Late-stage trials could commence within days. NVAX's vaccine can be stored at refrigerated temperatures. Mass doses could potentially be easier to distribute vis-a-vis PFE or MRNA.

Novavax: The COVID-19 Play Is Still Intact

GAITHERSBURG, Md., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Rick Crowley to the newly created position of Executive Vice President, Chief Operations Officer. In this role, Mr. Crowley will have leadership responsibility for all operations, including Quality, Manufacturing, Supply Chain and Regulatory Affairs. He takes over manufacturing from Ben Machielse, who will continue with the company as an executive advisor to the Chief Executive Officer, supporting the development of the COVID vaccine.

Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer

FuboTV

Sirius XM Holdings Inc

Sirius XM, fuboTV, and Novavax have the right stuff to reward risk-tolerant growth investors in the year ahead.

Got $600? Here Are 3 Hot Stocks to Buy Before 2021

Plug Power

Tesla

The world's largest cryptocurrency can't hold a candle to the returns of these high-flying stocks.

5 High-Growth Stocks That Crushed Bitcoin in 2020

Arcturus Therapeutics

3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now

CureVac B.V

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

4 Small COVID-19 Vaccine Makers to Look Out for in 2021

Novavax, Inc. (NASDAQ: NVAX), which has seen a delay in the start of the U.S. leg of the Phase 3 study of its coronavirus vaccine candidate, announced late Wednesday a vaccine supply deal. What Happened: Maryland-based Novavax said it has signed an advance purchase agreement with the New Zealand government for supplying 10.7 million doses of its investigational vaccine codenamed NVX-CoV2373.

Novavax Clinches 10.7M-Dose Coronavirus Vaccine Supply Deal With New Zealand

While Pfizer and Moderna enjoy first-to-market advantage, the reality is that being first in a vaccine race isn't always the best. Plus, Novavax's distinct approach could make NVAX stock a strong dark horse.

Novavax Can Still Make Coronavirus Vaccines Great Again

Bill Gates expects Novavax's vaccine to be effective against Covid-19. Despite Pfizer being first, NVAX stock is still bound to benefit.

The Vaccine Race Is Far From Over, And That's Good News for Novavax

Advance purchase agreement signed for NVX-CoV2373, Novavax' adjuvanted protein vaccine candidate Advance purchase agreement signed for NVX-CoV2373, Novavax' adjuvanted protein vaccine candidate

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine

They each have a key competitive edge that could set them apart.

3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic World

Blink Charging

3 Stocks That Turned $100,000 Into $1 Million in 2020

NVAX stock is up over 3,000% this year yet it's not the one with the doses on the streets. Best to trade the stock while they chase the headline.

Novavax Stock Leads the Board on Wall Street but Lags on Main Street

The development a Covid-19 vaccine is no longer a race to the finish line, but there are still plenty of reasons to buy NVAX stock. The post Novavax Stock Is an Underdog You Should Bank On appeared first on InvestorPlace.

Novavax Stock Is an Underdog You Should Bank On

Celldex Therapeutics

Co-Diagnostics

Seres Therapeutics

Nestle SA

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

News for Novavax Stock (NVAX)